Table 3. Baseline patient characteristics in the subgroup of “MAPS” phase II trial population.
| LDH cut-off | LDH ≤ UNR | LDH > UNR | |||
|---|---|---|---|---|---|
| No of patients (%) | 58 (82) | 13 (18) | |||
| Median Age (range) | 67 (45–77) | 66 (46–81) | |||
| n | % | n | % | p | |
| Treatment | |||||
| Sorafenib group | 31 | 53 | 6 | 46 | 0.635 |
| Non Sorafenib group | 27 | 47 | 7 | 54 | |
| Gender | |||||
| Male | 32 | 55 | 9 | 69 | 0.354 |
| Female | 26 | 45 | 4 | 31 | |
| Disease extent | |||||
| Locally advanced | 20 | 34 | 5 | 38 | 0.786 |
| Metastatic | 38 | 66 | 8 | 62 | |
| Primary tumour location | |||||
| Head | 31 | 53 | 8 | 62 | 0.596 |
| Other | 27 | 47 | 5 | 38 | |
| Biliary stenting | |||||
| Yes | 5 | 9 | 2 | 15 | 0.459 |
| No | 53 | 91 | 11 | 85 | |
| Metastatic sites location | |||||
| Hepatic | 24 | 41 | 6 | 46 | 0.753 |
| Extra-hepatic | 34 | 59 | 7 | 54 | |
| Metastatic site number | |||||
| 1 | 51 | 88 | 9 | 69 | 0.119 |
| 2 | 5 | 9 | 2 | 15 | |
| 3 | 2 | 3 | 1 | 8 | |
| ≥4 | 0 | 0 | 1 | 8 | |
| Karnofsky PS | |||||
| <70 | 16 | 28 | 4 | 31 | |
| ≥70 | 42 | 72 | 9 | 69 | |